Canadian Medical Association Journal · 2004 · 56 citations · 9 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunotherapyInflammationGastrointestinal InflammationImmunopathology Of Infectious DiseasesInflammatory Bowel DiseaseInflammatory Skin DiseasesInflammatory Skin DisordersSkin InfectionsCutaneous Crohn DiseaseImmunomodulatory AntibodiesImmunomodulatory BiologicsImmunomodulatory EffectsInflammatory Bowel Disease TherapyOpportunistic Cutaneous InfectionsOpportunistic Skin InfectionsTumor Necrosis Factor Inhibitor Therapy
Infliximab is a chimeric anti-tumour necrosis factor-alpha antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.
9
Goodman and Gilman's the Pharmacological Basis of Therapeutics
William H. Stigelman, D Pharm · Military Medicine · 1986 · 6.8K citations
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands, Frank Anderson, Çharles N. Bernstein et al. · New England Journal of Medicine · 2004 · 2.2K citations · Full text